Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Data from Quantification of Neoantigen-Mediated Immunoediting in Cancer Evolution

View through CrossRef
<div>Abstract<p>Immunoediting includes three temporally distinct stages, termed elimination, equilibrium, and escape, and has been proposed to explain the interactions between cancer cells and the immune system during the evolution of cancer. However, the status of immunoediting in cancer remains unclear, and the existence of neoantigen depletion in untreated cancer has been debated. Here we developed a distribution pattern-based method for quantifying neoantigen-mediated negative selection in cancer evolution. The method can provide a robust and reliable quantification for immunoediting signal in individual patients with cancer. Moreover, this method demonstrated the prevalence of immunoediting in the immunotherapy-naive cancer genome. The elimination and escape stages of immunoediting can be quantified separately, where tumor types with strong immunoediting-elimination exhibit a weak immunoediting-escape signal, and vice versa. The quantified immunoediting-elimination signal was predictive of clinical response to cancer immunotherapy. Collectively, immunoediting quantification provides an evolutionary perspective for evaluating the antigenicity of neoantigens and reveals a potential biomarker for precision immunotherapy in cancer.</p>Significance:<p>Quantification of neoantigen-mediated negative selection in cancer progression reveals distinct features of cancer immunoediting and can serve as a potential biomarker to predict immunotherapy response.</p></div>
Title: Data from Quantification of Neoantigen-Mediated Immunoediting in Cancer Evolution
Description:
<div>Abstract<p>Immunoediting includes three temporally distinct stages, termed elimination, equilibrium, and escape, and has been proposed to explain the interactions between cancer cells and the immune system during the evolution of cancer.
However, the status of immunoediting in cancer remains unclear, and the existence of neoantigen depletion in untreated cancer has been debated.
Here we developed a distribution pattern-based method for quantifying neoantigen-mediated negative selection in cancer evolution.
The method can provide a robust and reliable quantification for immunoediting signal in individual patients with cancer.
Moreover, this method demonstrated the prevalence of immunoediting in the immunotherapy-naive cancer genome.
The elimination and escape stages of immunoediting can be quantified separately, where tumor types with strong immunoediting-elimination exhibit a weak immunoediting-escape signal, and vice versa.
The quantified immunoediting-elimination signal was predictive of clinical response to cancer immunotherapy.
Collectively, immunoediting quantification provides an evolutionary perspective for evaluating the antigenicity of neoantigens and reveals a potential biomarker for precision immunotherapy in cancer.
</p>Significance:<p>Quantification of neoantigen-mediated negative selection in cancer progression reveals distinct features of cancer immunoediting and can serve as a potential biomarker to predict immunotherapy response.
</p></div>.

Related Results

Immunological analysis of hybrid neoantigen peptide encompassing class I/II neoepitope-pulsed dendritic cell vaccine
Immunological analysis of hybrid neoantigen peptide encompassing class I/II neoepitope-pulsed dendritic cell vaccine
Neoantigens/ are tumor-specific antigens that evade central immune tolerance mechanisms in the thymus. Long-term tumor-specific cytotoxic T lymphocyte activity maintenance requires...
An immunoediting map of human cancers
An immunoediting map of human cancers
AbstractUnderstanding how cancer immunoediting sculpts tumor microenvironments is essential to disentangling tumor immune evasion mechanisms and developing immunotherapies. Here, w...
Neoantigens elicit T cell responses in breast cancer
Neoantigens elicit T cell responses in breast cancer
Abstract Neoantigens are tumor-specific antigens that arise from non-synonymous mutations in tumor cells. However, their effect on the immune responses in tumor microenviro...
Advances in Neoantigen-Based Cancer Vaccines
Advances in Neoantigen-Based Cancer Vaccines
Neoantigen-based immunotherapies harness somatic mutations as tumor-specific targets and represent a major advance in personalized cancer treatment. Since neoantigens are presented...
Tumor neoantigen heterogeneity impacts bystander immune inhibition of pancreatic cancer growth
Tumor neoantigen heterogeneity impacts bystander immune inhibition of pancreatic cancer growth
Abstract The threshold for immunogenic clonal fraction in a heterogeneous solid tumor required to induce effective bystander killing of non-immunogenic subclones is...
Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer
Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer
Background/Objectives: Neoantigens have attracted attention as ideal therapeutic targets for anti-tumour immunotherapy because the T cells that respond to neoantigens are not affec...
Neoantigen polypeptide vaccines induce effective antitumor response in colorectal cancer
Neoantigen polypeptide vaccines induce effective antitumor response in colorectal cancer
Abstract Background: The role of neoantigens in cancer immunotherapy is crucial. However, the effectiveness and safety of personalized neoantigen vaccines in colorectal can...

Back to Top